Pattern hair loss affects an estimated 50 million men and 30 million women in the U.S., yet no new drug for the condition has won approval since the late 1990s. That drought is now fueling one of the market's sharpest biotech rallies.
Shares of Veradermics Inc., which trades under the ticker 'MANE,' have climbed nearly 500% since the company went public in February. Absci Corp.'s stock has more than doubled so far in 2026. Cosmo NV has posted positive results for an experimental male hair-loss treatment, though its Zurich-listed shares have lagged the gains of its U.S. rivals.
The current standard of care — over-the-counter minoxidil (Rogaine) and prescription finasteride (Propecia) — carries side effects including heart palpitations and lowered libido, according to the source material. That gap has left an opening for new entrants, and investors are pricing it accordingly.
Cosmo's topical treatment, clascoterone, blocks the hormone responsible for male-pattern hair loss directly at the follicle. The company calls it the 'single biggest opportunity' in its portfolio and plans to file a new drug application with U.S. regulators in the first quarter of 2027. Jefferies analysts project global sales for the therapy could reach $3 billion, 'assuming a capable commercial partner is successfully found,' and expect Cosmo shares to nearly double over the next 12 months.
Veradermics reported positive results in April for a tablet form of minoxidil in male-pattern hair loss, followed by promising mid-stage data in July for women with thinning hair — a therapy that, if approved by the FDA, would become the first pill cleared for female-pattern hair loss. Absci is developing ABS-201, an AI-designed injectable candidate, with interim data expected in the second half of this year.
Jefferies analyst Roger Song, who holds the Street's highest price target on Veradermics, noted the market can support several winners at once: 'Many hair loss patients tend to use multiple drugs, either prescription or over-the-counter — as long as they can afford it — because it's a cash-pay market.'
The comparison on every trading desk is GLP-1s, the obesity drugs that pushed Eli Lilly & Co.'s market value past $1 trillion and briefly made Novo Nordisk A/S the most valuable company in Europe. But hair-loss drugs face a structural difference: baldness is not a medical emergency, so these treatments are unlikely to secure insurance coverage the way weight-loss drugs eventually did.
That is precisely why the sector deserves attention. This is capital chasing a purely voluntary transaction — millions of consumers deciding, with their own money, what a treatment is worth to them, with no mandate, no subsidy and no bureaucrat setting the price. The market has already voted with roughly $60 billion in obesity-drug precedent, and it is now placing early bets on hair loss using the same logic: real demand, real willingness to pay, and a regulator whose approval clock investors are pricing in real time.
Risk remains real — drug development fails far more often than it succeeds, and a prior generation of obesity treatments went bankrupt before GLP-1s broke through. But the lesson for the taxpayer is a comforting one: this entire boom, win or lose, will be financed by consumers and shareholders, not by Washington.
